earnings
confidence high
sentiment positive
materiality 0.75
ResMed Q3 FY2025: revenue $1.29B (+8%), GAAP EPS $2.48 (+22%), non-GAAP EPS $2.37 (+11%)
RESMED INC
2025-Q3 EPS
reported $6.93
vs consensus $2.58
▲ beat
(+168.6%)
- Revenue of $1.29B (+8% YoY; +9% constant currency); GAAP diluted EPS $2.48 vs $2.04 (+22%).
- Gross margin improved 140 bps to 59.3%; non-GAAP gross margin 59.9%.
- Operating income up 14% to $426.3M; non-GAAP operating income up 13% to $444.6M.
- Operating cash flow of $579M in the quarter.
- Quarterly dividend of $0.53/share declared; payable June 12, 2025 to holders of record May 8, 2025.